Chemical structure

化学结构
  • 文章类型: Journal Article
    背景:人参C.A.Mey是一种珍贵的药用资源,可用于治疗多种疾病。皂苷是最重要的生物活性成分,和稀有人参皂苷(Rg3,Rh2,Rk1和Rg5等。)是指人参皂苷通过脱水和脱水反应产生的化学结构变化,获得更容易被人体吸收,活性更高的三萜类化合物。
    目标:目前,人参的研究.广泛专注于抗癌相关方面,关于稀有人参皂苷的抗菌和皮肤保护作用的研究很少。本文综述了与细菌抑制和皮肤保护有关的稀有人参皂苷,为人参的研究提供了新的方向。
    方法:PubMed和WebofScience在2002年1月至2024年3月期间发表的关于人参的英文研究进行了检索。对选定的手稿进行了手动评估,以获取其他相关参考。这篇综述包括基础科学文章和相关研究,如前瞻性和回顾性队列研究。
    结论:本文总结了几种稀有人参皂苷的最新研究进展,讨论了稀有人参皂苷的抗菌作用,发现人参皂苷在使用过程中可以有效保护皮肤,促进伤口愈合,从而发挥有效的抗菌作用,并进一步探索人参的其他药用价值。本综述有望为人参药物的进一步研究和开发提供更广泛的认识和新思路。
    BACKGROUND: Panax ginseng C. A. Mey is a precious medicinal resource that could be used to treat a variety of diseases. Saponins are the most important bioactive components of, and rare ginsenosides (Rg3, Rh2, Rk1 and Rg5, etc.) refer to the chemical structure changes of primary ginsenosides through dehydration and desugarization reactions, to obtain triterpenoids that are easier to be absorbed by the human body and have higher activity.
    OBJECTIVE: At present, the research of P. ginseng. is widely focused on anticancer related aspects, and there are few studies on the antibacterial and skin protection effects of rare ginsenosides. This review summarizes the rare ginsenosides related to bacterial inhibition and skin protection and provides a new direction for P. ginseng research.
    METHODS: PubMed and Web of Science were searched for English-language studies on P. ginseng published between January 2002 and March 2024. Selected manuscripts were evaluated manually for additional relevant references. This review includes basic scientific articles and related studies such as prospective and retrospective cohort studies.
    CONCLUSIONS: This paper summarizes the latest research progress of several rare ginsenosides, discusses the antibacterial effect of rare ginsenosides, and finds that ginsenosides can effectively protect the skin and promote wound healing during use, so as to play an efficient antibacterial effect, and further explore the other medicinal value of ginseng. It is expected that this review will provide a wider understanding and new ideas for further research and development of P. ginseng drugs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    巨噬细胞向肌成纤维细胞的转变(MMT)已被报道为肾脏纤维化的新关键靶标。枸杞是一种改善肾功能的传统中药,其中其多糖(LBP)是主要的活性成分。然而,LBP在治疗肾纤维化中的作用是否与MMT过程相关尚不清楚.本研究的目的是探讨LBPs对MMT过程的调节作用与抗纤维化作用之间的关系。最初,首先通过SephadexG-100柱分离小分子量LBP馏分(LBP-S)。然后,在TGF-β诱导的骨髓源性巨噬细胞(BMDM)模型上,LBP-S对MMT过程的有效抑制作用。随后,通过单糖阐明了LBP-S的化学结构,甲基化和NMR光谱分析。体内生物分布特征研究表明,通过腹膜内给药,LBP-S在肾脏中表现出有效的积累。最后,LBP-S对单侧输尿管梗阻手术(UUO)小鼠表现出满意的抗肾纤维化作用,巨噬细胞耗竭后显著减少。总的来说,我们的研究结果表明,LPB-S可通过调节MMT过程缓解肾脏纤维化,为慢性肾脏病(CKD)相关纤维化治疗提供新的候选药物.
    The macrophage to myofibroblasts transition (MMT) has been reported as a newly key target in renal fibrosis. Lycium barbarum L. is a traditional Chinese medicine for improving renal function, in which its polysaccharides (LBPs) are the mainly active components. However, whether the role of LBPs in treating renal fibrosis is related to MMT process remain unclear. The purpose of this study was to explore the relationship between the regulating effect on MMT process and the anti-fibrotic effect of LBPs. Initially, small molecular weight LBPs fractions (LBP-S) were firstly isolated via Sephadex G-100 column. Then, the potent inhibitory effect of LBP-S on MMT process was revealed on bone marrow-derived macrophages (BMDM) model induced by TGF-β. Subsequently, the chemical structure of LBP-S was elucidated through monosaccharide, methylation and NMR spectrum analysis. In vivo biodistribution characteristics studies demonstrated that LBP-S exhibited effectively accumulation in kidney via intraperitoneal administration. Finally, LBP-S showed a satisfactory anti-renal fibrotic effect on unilateral ureteral obstruction operation (UUO) mice, which was significantly reduced following macrophage depletion. Overall, our findings indicated that LPB-S could alleviate renal fibrosis through regulating MMT process and providing new candidate agents for chronic kidney disease (CKD) related fibrosis treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    我们先前报道的HDAC6抑制剂(HDAC6i)Marbostat-100(4)为进一步的临床评估提供了许多论据。通过4的酸性氢取代不同的碳残基,我们能够产生一个全碳立体中心,显著提高了抑制剂的水解稳定性。进一步的不对称合成已显示(S)构型的抑制剂优先结合HDAC6。这导致了高选择性和有效的甲基取代衍生物S-29b,在MV4-11细胞中引起持久的微管蛋白过度乙酰化。最后,HDAC6/S-29b复合物的晶体结构为合成化合物系列的高效能和立体选择性提供了机理解释。
    Our previously reported HDAC6 inhibitor (HDAC6i) Marbostat-100 (4) has provided many arguments for further clinical evaluation. By the substitution of the acidic hydrogen of 4 for different carbon residues, we were able to generate an all-carbon stereocenter, which significantly improves the hydrolytic stability of the inhibitor. Further asymmetric synthesis has shown that the (S)-configured inhibitors preferentially bind to HDAC6. This led to the highly selective and potent methyl-substituted derivative S-29b, which elicited a long-lasting tubulin hyperacetylation in MV4-11 cells. Finally, a crystal structure of the HDAC6/S-29b complex provided mechanistic explanation for the high potency and stereoselectivity of synthesized compound series.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    为了促进富含鼠李糖半乳糖醛酸-I(RG-I)的果胶(RGP)作为新的应用,健康,和胶凝食品添加剂,本研究通过四种方法(碱:AK,高温/压力:TP,柠檬酸:CA,和酶辅助:EA提取)。AK和CA产生的果胶具有最高的RG-I比例(54.8%和51.9%,分别)通过破坏同半乳糖醛酸区域;TP和EA使RG-I比例增加了约10%。在这四种方法中,AK诱导最低的酯化度(DE)(6.7%)和较长的侧链形成强缠结,有助于其最高的凝胶硬度。CARGP的相对低的DE(18.5%)促进了稳定的凝胶形成。值得注意的是,其高度支化的RG-I区提供了更多的分子内疏水相互作用,使更高度交联的凝胶网络具有更好的凝胶回弹性。相比之下,TP诱导最高的DE(57%)和弯曲的分子链;它抑制Ca2结合,纠缠,和分子内疏水相互作用,因此没有凝胶形成。EARGP与最低分子大小相关,使得Ca2+更难形成链接,结果没有凝胶。这些发现提供了对提取方法之间关系的见解,分子结构,和RGP的胶凝特性。
    To facilitate the application of rhamnogalacturonan-I (RG-I)-enriched pectins (RGPs) as novel, healthy, and gelling food additives, this study compared the structural characteristics and gelling properties of RGPs extracted from citrus peel via four methods (alkali: AK, high-temperature/pressure: TP, citric acid: CA, and enzyme-assisted: EA extractions). AK and CA yielded pectins with the highest RG-I proportions (54.8 % and 51.9 %, respectively) by disrupting the homogalacturonan region; TP and EA increased the RG-I proportions by ~10 %. Among the four methods, AK induced the lowest degree of esterification (DE) (6.7 %) and longer side chains that form strong entanglement, contributing to its highest gel hardness. The relatively low DE (18.5 %) of CA RGP facilitated stable gel formation. Notably, its highly branched RG-I region afforded more intramolecular hydrophobic interactions, making a more highly cross-linked gel network of better gel resilience. In contrast, TP induced the highest DE (57 %) and curved molecular chains; it inhibited Ca2+ binding, entanglement, and intramolecular hydrophobic interactions, and thus no gel formed. EA RGP was associated with the lowest molecular size, rendering it more difficult for Ca2+ to form links, which resulted no gel. These findings offer insights into the relationship among the extraction methods, molecular structures, and gelling properties of RGPs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    天麻(G.elata),被列为34种珍贵中药之一,服务器作为药草和食物来源的双重目的。多糖是G.elata的主要活性成分,具有免疫调节等药理活性,抗氧化,抗癌,抗衰老,神经保护和抗菌活性等。G.elata多糖(GPs)的生物活性与其化学结构密切相关。然而,目前尚无综述对GPs的化学结构和药理活性进行综合总结。这项研究深入研究了化学结构,GPs的药理作用,为这些化合物的未来发展和应用提供见解。
    Gastrodia elata Blume (G. elata), listed as one of the 34 precious Chinese medicines, servers a dual purpose as both a medicinal herb and a food source. Polysaccharide is the main active ingredient in G. elata, which has pharmacological activities such as immune regulation, anti-oxidation, anti-cancer, anti-aging, neuroprotection and antibacterial activity and so on. The biological activities of G. elata polysaccharide (GPs) is closely related to its chemical structures. However, no a review has synthetically summarized the chemical structures and pharmacological activities of GPs. This study delves into the chemical structures, pharmacological action of GPs, offering insights for the future development an application of these compounds.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Editorial
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    阿片类药物是μ阿片受体(μOR)的小分子激动剂,而逆转剂如纳洛酮是μOR的拮抗剂。这里,我们开发了机器学习(ML)模型,以基于SMILES字符串和二维分子描述符对人类μOR处配体的内在活动进行分类。我们首先手动整理了983个小分子的数据库,在人μOR下测量了Emax值。化学空间的分析允许鉴定优势支架和结构相似的激动剂和拮抗剂。然后训练决策树模型和定向消息传递神经网络(MPNN)以对激动和拮抗配体进行分类。树(ET)和MPNN模型的保持性测试AUC(接受者操作曲线下的面积)分别为91.5±3.9%和91.8±4.4%,分别。为了克服小数据集的挑战,使用由15,816个人类配体组成的未标记数据集测试了一种称为“不一致”的师生学习方法,鼠标,和大鼠μOR,κOR,和δOR。我们发现tritrinating方案能够将MPNN模型的保留AUC提高到高达95.7%。我们的工作证明了开发ML模型以准确预测μOR配体的内在活性的可行性,即使数据有限。我们设想这些模型在评估未表征的公共安全风险物质以及发现新的治疗药物以抵消阿片类药物过量方面的潜在应用。
    Opioids are small-molecule agonists of μ-opioid receptor (μOR), while reversal agents such as naloxone are antagonists of μOR. Here, we developed machine learning (ML) models to classify the intrinsic activities of ligands at the human μOR based on the SMILES strings and two-dimensional molecular descriptors. We first manually curated a database of 983 small molecules with measured Emax values at the human μOR. Analysis of the chemical space allowed identification of dominant scaffolds and structurally similar agonists and antagonists. Decision tree models and directed message passing neural networks (MPNNs) were then trained to classify agonistic and antagonistic ligands. The hold-out test AUCs (areas under the receiver operator curves) of the extra-tree (ET) and MPNN models are 91.5 ± 3.9% and 91.8 ± 4.4%, respectively. To overcome the challenge of a small data set, a student-teacher learning method called tritraining with disagreement was tested using an unlabeled data set comprised of 15,816 ligands of human, mouse, and rat μOR, κOR, and δOR. We found that the tritraining scheme was able to increase the hold-out AUC of MPNN models to as high as 95.7%. Our work demonstrates the feasibility of developing ML models to accurately predict the intrinsic activities of μOR ligands, even with limited data. We envisage potential applications of these models in evaluating uncharacterized substances for public safety risks and discovering new therapeutic agents to counteract opioid overdoses.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    一种新的多糖,命名为SP40015A01,是通过水提取从防风中获得的,分离和纯化。SP40015A01(9.7×105Da)由鼠李糖(Rha)组成,半乳糖醛酸(GalA),半乳糖(Gal),和阿拉伯糖(Ara)的比例为1.6:85.6:5.8:7.6。SP40015A01的主链由3-α-GalAp组成,2-α-GalAp,2,3-β-GalAp和2,3-β-Galp,并在2,3-β-GalAp的C3处分支,2,3-β-Galp的C3。斑马鱼实验用于探索SP40015A01的免疫调节活性。结果表明,SP40015A01能显著提高免疫低下斑马鱼的中性粒细胞密度,降低一氧化氮(NO)和白细胞介素-1β(IL-1β)的含量。这项研究表明,SP40015A01具有显著的免疫调节活性,能提高中性粒细胞密度,降低炎症因子含量,提示SP40015A01可能是防风(SR)治疗免疫相关疾病的潜在免疫调节剂。本研究补充了中药多糖成分的研究,为SR的开发和临床应用提供了科学的解释。
    A new polysaccharide, named SP40015A01, was obtained from Saposhnikoviae Radix by water extraction, isolation and purification. SP40015A01 (9.7 × 105 Da) is composed of Rhamnose (Rha), Galacturonic acid (GalA), Galactose (Gal), and Arabinose (Ara) with the proportion of 1.6:85.6:5.8:7.6. The backbone of SP40015A01 is composed of 3-α-GalAp, 2-α-GalAp, 2,3-β-GalAp and 2,3-β-Galp, and branched at C3 of 2,3-β-GalAp, C3 of 2,3-β-Galp. Zebrafish experiments were used to explore the immunomodulatory activity of SP40015A01. Results showed that SP40015A01 could significantly improve the neutrophils density of immunocompromised zebrafish and reduce the content of nitric oxide (NO) and interleukin-1β (IL-1β). This study demonstrated that SP40015A01 has significant immunomodulatory activity, which can improve the neutrophils density and reduce inflammatory factor content, suggesting SP40015A01 may be a potential immunomodulator in Saposhnikoviae Radix (SR) for treatment of hypoimmunity related disease. This study supplemented the research on the polysaccharide components in traditional Chinese medicine and provided a scientific explanation for the development and clinical applications of SR.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    小干扰RNA(siRNA)正在彻底改变肝脏相关适应症的治疗。然而,强大的传递到肝外组织仍然是一个挑战。缀合脂质(例如,二十二烷酸[DCA])对siRNA支持肝外递送,但是组织积累仍然低于批准的siRNA疗法在肝脏中实现的积累。早期证据表明,用头组将DCA功能化(例如,磷脂酰胆碱[PC])可以增强对某些组织的递送。这里,我们报告了首次系统评估PC头组化学对DCA缀合的siRNA肝外分布的影响。我们表明,用PC头部基团功能化DCA可增强siRNA在心脏中的积累,肌肉,肺,胰腺,十二指肠,膀胱,和脂肪。改变PC头部基团的磷酸盐和胆碱部分之间的接头的大小改变了siRNA的肝外积累,最佳接头长度对于不同的组织是不同的。PC头组效价的增加也以组织特异性方式改善了肝外积累。这项研究证明了PC部分对脂质缀合的siRNA的生物分布的结构影响,并引入了多种新型PC变体用于DCA缀合的siRNA的化学优化。这些化学变体可用于其他脂质的背景中,以增加用于siRNA的肝外分布的缀合物的库。
    Small interfering RNAs (siRNAs) are revolutionizing the treatment of liver-associated indications. Yet, robust delivery to extrahepatic tissues remains a challenge. Conjugating lipids (e.g., docosanoic acid [DCA]) to siRNA supports extrahepatic delivery, but tissue accumulation remains lower than that achieved in liver by approved siRNA therapeutics. Early evidence suggests that functionalizing DCA with a head group (e.g., phosphatidylcholine [PC]) may enhance delivery to certain tissues. Here, we report the first systematic evaluation of the effect of PC head group chemistry on the extrahepatic distribution of DCA-conjugated siRNAs. We show that functionalizing DCA with a PC head group enhances siRNA accumulation in heart, muscle, lung, pancreas, duodenum, urinary bladder, and fat. Varying the size of the linker between the phosphate and choline moiety of the PC head group altered the extrahepatic accumulation of siRNA, with the optimal linker length being different for different tissues. Increasing PC head group valency also improved extrahepatic accumulation in a tissue-specific manner. This study demonstrates the structural impact of the PC moiety on the biodistribution of lipid-conjugated siRNA and introduces multiple novel PC variants for the chemical optimization of DCA-conjugated siRNA. These chemical variants can be used in the context of other lipids to increase the repertoire of conjugates for the extrahepatic distribution of siRNAs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:有时长期难以预测治疗药物和毒性药物的临床疗效和潜在风险。因此,需要进行文献检索以评估临床实践中使用的药物的毒性和较低功效的原因。
    方法:因此,搜索有关理化性质的文献,化学式,分子量,pH值,电离,受体类型,激动剂和拮抗剂,治疗性的,化合物与药效团和毒性团的毒性和结构-活性关系,以确定高效和相对低毒性的药物。纳入标准是在PubMed上发表的手稿,Scopus,WebofScience,PubMedCentral,谷歌学者等等,1960年至2023年。关键词如药效团,毒物,结构-活动-关系和疾病也在那里搜索。排除标准是缺乏药效团的化学物质,1960年以前出版的有毒物质和手稿。
    结果:研究结果表明,药效基团和毒性基团决定了治疗的临床疗效和安全性,但是如果它们重叠,治疗和毒性作用同时发生。因此,官能团,剂量,共同给药和药物在受体的浓度,药物-受体结合和受体结合的持续时间是药效团和毒性团活性的决定因素。分子质量,化学配置,pH值,受体亲和力和结合能力,多种药效,该化学物质的亲水/亲脂性质极大地有助于药效团和毒性团的功能性。
    结论:每日单一治疗,避免可逆药理学,具有共价加合物的药物,维持治疗剂量,并且使用多种药效团来治疗终末期疾病将使毒性最小化并提高疗效。
    OBJECTIVE: Sometimes clinical efficacy and potential risk of therapeutic and toxic agents are difficult to predict over a long period of time. Hence there is need for literature search with a view to assessing cause of toxicity and less efficacy of drugs used in clinical practice.
    METHODS: Hence literatures were searched for physicochemical properties, chemical formulas, molecular masses, pH values, ionization, receptor type, agonist and antagonist, therapeutic, toxic and structure-activity relationship of chemical compounds with pharmacophore and toxicophore, with a view to identifying high efficacious and relative low toxic agents. Inclusion criteria were manuscripts published on PubMed, Scopus, Web of Science, PubMed Central, Google Scholar among others, between 1960 and 2023. Keywords such as pharmacophore, toxicophore, structure-activity-relationship and disease where also searched. The exclusion criteria were the chemicals that lack pharmacophore, toxicophore and manuscripts published before 1960.
    RESULTS: Findings have shown that pharmacophore and toxicophore functional groups determine clinical efficacy and safety of therapeutics, but if they overlap therapeutic and toxicity effects go concurrently. Hence the functional groups, dose, co-administration and concentration of drugs at receptor, drug-receptor binding and duration of receptor binding are the determining factors of pharmacophore and toxicophore activity. Molecular mass, chemical configuration, pH value, receptor affinity and binding capacity, multiple pharmacophores, hydrophilic/lipophilic nature of the chemical contribute greatly to functionality of pharmacophore and toxicophore.
    CONCLUSIONS: Daily single therapy, avoidance of reversible pharmacology, drugs with covalent adduct, maintenance of therapeutic dose, and the use of multiple pharmacophores for terminal diseases will minimize toxicity and improve efficacy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号